In the U.S., the drug pandemic claims over 300 lives daily, prompting experts to redefine the crisis’s nature. Synthetic opioids infiltrate the market, camouflaged as legitimate medications, leading to a devastating impact, particularly among young people.
InterOme, a frontrunner in public health, champions its advanced solution “PULSE.” This user-friendly digital health platform leverages real-time data analysis, amalgamating individual, public, and asset health data into a centralized geospatial database. Its power lies in monitoring drug trends through anonymous wastewater analysis, revolutionizing drug exposure assessment.
The whitepaper addresses the gravity of the drug crisis and introduces the PULSE platform as a potent weapon against drug poisoning. Developed with Brevi-T Bio, InterOme’s wastewater drug monitoring service offers empirical evidence to accurately gauge drug usage, enabling informed decision-making while maintaining individual privacy.
PULSE showcases technology’s might in combating public health crises, unveiling patterns, predicting trends, and empowering authorities with actionable insights. The newly established non-profit, “Hopeful Life,” amplifies impact through interdisciplinary collaboration.
As the drug crisis persists, the whitepaper asserts real-time, accurate information coupled with proactive interventions can bring meaningful change. The collaboration between InterOme, Brevi-T Bio and Hopeful Life reflects a commitment to saving lives and communities. In pursuit of a safer tomorrow, the white paper’s insights mark a critical stride forward.
For more information visit www.hopefullife.org.
To download the full press release, please visit www.brevitbio.com or www.interome.com
Media Contact
Corina Shtir, InterOme, 1 858-294-0204, [email protected], www.interome.com
SOURCE InterOme
